23 stories found
President Trump announced that the ceasefire between Israel and Lebanon has been extended by an additional three weeks. This extension aims to continue de-escalation efforts in the region.
Sanofi and Regeneron's drug Dupixent has received approval, becoming the first biologic treatment available for children under 12 suffering from chronic spontaneous urticaria (CSU).
Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a strategic collaboration to co-develop novel radiopharmaceutical therapies, combining their expertise in oncology and drug development.
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
Pharmaceutical company Regeneron has gained approval for an extended 20-week dosing regimen for its drug Eylea HD.
An article examines the investment potential of Regeneron Pharmaceuticals, Inc. (REGN) for prospective stock purchasers.
Several financial firms have issued new ratings, price targets, or coverage initiations for biotech and pharmaceutical companies including Beam Therapeutics, Krystal Biotech, 4D Molecular Therapeutics, BioMarin Pharmaceutical, Vertex Pharmaceuticals, CRISPR Therapeutics AG, Regeneron Pharmaceuticals, and UniQure.
Analysts are offering their latest comments and assessments regarding Regeneron Pharmaceuticals (REGN).
The U.S. Food and Drug Administration has approved the first gene therapy designed to restore hearing in children with a rare form of inherited deafness. This breakthrough offers new hope for those affected by congenital hearing loss.
Regeneron Pharmaceuticals (REGN) has announced a new collaboration agreement with Telix Pharmaceuticals Limited, signaling a joint effort in pharmaceutical development.
Sanofi and Regeneron's drug Dupixent has received approval in the European Union for treating young children suffering from chronic urticaria, expanding its use for pediatric patients.
Biotechnology company Regeneron Pharmaceuticals expects to incur approximately $102 million in pre-tax in-process research and development charges for the first quarter.
Piper Sandler has upgraded Regeneron Pharmaceuticals to an 'overweight' rating, citing strong performance from its drug Dupixent and the potential of its robust pipeline.
An analysis questions whether Regeneron Pharmaceuticals stock is underperforming relative to the broader Nasdaq index.
Regeneron has been granted FDA priority review for its therapy targeting a rare bone disorder, potentially accelerating its path to market.
Amid escalating tensions with Iran, European nations and the UK are discussing plans to secure the Strait of Hormuz. The US has increased its naval presence in the region and issued warnings to Iran, with reports of a US naval blockade advancing into international waters.
An earnings preview outlines expectations for Regeneron Pharmaceuticals' upcoming financial report.
Jim Cramer provided his assessment of D-Wave, expressing reservations about its business model and referring to it as more of a 'science project' than a solid investment.
Former President Trump has imposed 100% tariffs on prescription drugs from companies that have not agreed to lower prices, a move aimed at incentivizing domestic production and reducing drug costs in the United States.
Regeneron Pharma (REGN) shares have risen after Jim Cramer publicly called it a good stock.
Jim Cramer expresses regret over not investing in Regeneron, saying, “I Should Have Pulled the Trigger on Regeneron.”
Regeneron and Sanofi have announced that their drug Dupixent has received a label expansion, allowing it to be used for the treatment of allergic fungal rhinosinusitis.